Clinical Trial

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Study acronym: iStopMM
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 16, 2019 (before its estimated January 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-01-23; most recent amendment 2019-08-14.
Status change: Not Yet Recruiting → Enrolling by Invitation 2019-08-14
Trial Details
NCT Number NCT03815279
Lead Sponsor Landspitali University Hospital
Collaborators: Amgen, Celgene, University of Iceland, Memorial Sloan Kettering Cancer Center
Conditions Multiple Myeloma, Smoldering Multiple Myeloma
Enrollment 80 participants
Start Date 2019-06-24
Primary Completion 2024-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2019-08-16